Louai Labanieh

This paper develops GELYTACs, lysosome-targeting chimeras that deplete IgG in vivo via AAV delivery, showing sustained antibody depletion in mice.

The paper describes the development of genetically encodable LYTACs (GELYTACs) for targeted protein degradation using engineered T-cells, showing efficacy in secreting and delivering the therapeutics.

This paper introduces a novel CAR T cell platform using proximal T cell signaling molecules to enable Boolean logic-gated control, improving efficacy and reducing off-tumor toxicity.

This paper introduces CRISPR ChaCha, a GPCR-Coupled CRISPR-Cas system that converts extracellular signals into genetic programs, showing improved performance over existing systems.